Immunodeficiency 56 (IMD56) Cell Models for Research

Immunodeficiency 56 (IMD56) is an extremely rare primary immunodeficiency disorder, with only a handful of cases reported worldwide. It is caused by autosomal recessive mutations in the ZNF341 gene, leading to a hyper-IgE syndrome (HIES)-like phenotype. Patients typically present with recurrent skin and pulmonary infections, elevated serum IgE levels, and skeletal and connective tissue abnormalities. The disease is often misdiagnosed or undiagnosed due to its rarity and clinical overlap with other HIES forms. According to the National Institutes of Health (NIH) Genetic and Rare Diseases Information Center, the prevalence is unknown, but it is estimated to affect fewer than 1 in 1,000,000 individuals. Early diagnosis is critical for managing infections and improving quality of life, but the molecular mechanisms underlying the immune dysregulation remain poorly understood, highlighting the need for research models.

IMD56 provides a unique opportunity to study the role of ZNF341 in immune regulation and STAT3 signaling. ZNF341 is a transcription factor that regulates the expression of STAT3, a key mediator of cytokine signaling. Mutations in ZNF341 lead to reduced STAT3 expression and impaired Th17 cell differentiation, explaining the susceptibility to fungal and bacterial infections. Because the disease is monogenic and well-defined, it serves as an excellent model for studying the molecular basis of primary immunodeficiencies. Furthermore, the availability of patient-derived cell lines and the ability to generate isogenic gene-edited models allow researchers to dissect the precise mechanisms of ZNF341 function. Open questions include the full spectrum of ZNF341 target genes, its interaction with other transcription factors, and the potential for targeted therapies to restore STAT3 expression.

Although IMD56 is not a cancer predisposition syndrome, the dysregulated immune pathways have implications for tumor surveillance. The primary pathway affected is the JAK-STAT signaling cascade. In normal cells, cytokine binding to receptors activates JAK kinases, which phosphorylate STAT3, leading to its dimerization and nuclear translocation. STAT3 then regulates genes involved in cell proliferation, survival, and immune responses. In IMD56, ZNF341 deficiency results in reduced STAT3 transcription, leading to impaired Th17 cell differentiation and altered cytokine production. This pathway is critical for the differentiation of CD4+ T cells into Th17 cells, which produce IL-17 and are essential for mucosal immunity against extracellular pathogens. Additionally, STAT3 is involved in the regulation of acute-phase response genes and anti-apoptotic proteins, and its dysregulation can affect the tumor microenvironment. While IMD56 itself is not oncogenic, the immune defects may increase susceptibility to certain infections that are associated with cancer, such as human papillomavirus (HPV).

Data from ClinVar and the Human Gene Mutation Database (HGMD) indicate that all reported IMD56 cases carry biallelic mutations in ZNF341. The most common mutations are nonsense and frameshift, resulting in premature stop codons and likely nonsense-mediated decay of the mRNA. Some missense mutations have also been reported, affecting the zinc finger domains and DNA-binding ability of ZNF341. The functional effect is a loss of ZNF341 transcriptional activity, leading to reduced STAT3 mRNA and protein levels.

The primary deregulated network is the JAK-STAT signaling pathway, specifically the STAT3 axis. Key nodes include:

• • ZNF341: Transcription factor that binds to the STAT3 promoter and enhances its expression.
• • STAT3: Signal transducer and transcription activator that mediates responses to IL-6, IL-10, IL-21, and other cytokines.
• • Th17 cells: CD4+ T cells that produce IL-17, IL-21, and IL-22, crucial for mucosal immunity.
• • IL-17: Pro-inflammatory cytokine that recruits neutrophils and induces antimicrobial peptides.
• • RORγt: Lineage-specific transcription factor for Th17 cells, whose expression is dependent on STAT3.

In IMD56, reduced STAT3 leads to decreased RORγt expression and impaired Th17 differentiation, resulting in susceptibility to Candida and Staphylococcus infections. Additionally, STAT3 is involved in the regulation of anti-apoptotic proteins such as Bcl-2 and Mcl-1, and its deficiency may affect the survival of immune cells. The network also intersects with the MAPK and PI3K/AKT pathways, as STAT3 can be activated by non-canonical pathways, but the primary defect in IMD56 is the transcriptional regulation of STAT3.

Organoids, particularly intestinal and lung organoids, can be derived from patient iPSCs and used to study epithelial barrier function and immune interactions. However, for immune cell studies, 2D cell lines are more commonly used. Gene-edited cell lines with ZNF341 knockout or knock-in mutations are essential for functional studies.

Animal models for IMD56 are limited, but several approaches are used:

• • ZNF341 knockout mice: Generated using CRISPR/Cas9 to disrupt the ZNF341 gene. These mice exhibit reduced STAT3 expression and impaired Th17 differentiation, recapitulating key features of the human disease.
• • Patient-derived xenograft (PDX) models: Not commonly used for immunodeficiencies, but human immune cells from patients can be transferred into immunodeficient mice (e.g., NSG mice) to study immune function in vivo.
• • Genetically engineered mouse models (GEMM): Conditional knockouts of ZNF341 in T cells using Cre-lox systems allow tissue-specific deletion.
• • Induced models: Use of siRNA or shRNA to knockdown ZNF341 in cell lines or in vivo via viral vectors.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise ZNF341 mutations. These models are invaluable for studying the molecular consequences of specific mutations and for drug screening. Examples include:

• • ZNF341 knockout cell lines: Generated by introducing a frameshift mutation in exon 2 of ZNF341, leading to a premature stop codon. These cells show reduced STAT3 expression and impaired Th17 differentiation when differentiated into T cells.
• • ZNF341 point mutation knock-in lines: For example, introducing a missense mutation (e.g., p.Arg399Trp) that affects the DNA-binding domain, allowing the study of hypomorphic alleles.
• • Reporter lines: ZNF341 promoter-driven GFP or luciferase reporters can be used to monitor ZNF341 expression in real-time.

These gene-edited models are commercially available from several sources, ensuring sequence verification and quality control. They accelerate research by providing consistent, reproducible models that can be used in high-throughput screens.

Gene-edited cell lines are essential for functional genomics studies to validate the role of ZNF341 in immune function. For example, ZNF341 knockout Jurkat cells can be used to assess the impact on STAT3 expression and downstream signaling. By comparing wild-type and knockout cells, researchers can identify ZNF341-dependent genes through transcriptomic and proteomic analyses. Additionally, complementation assays with wild-type ZNF341 can confirm the specificity of the phenotype. These models also enable the study of ZNF341 interactions with other transcription factors, such as STAT3 and RORγt, using co-immunoprecipitation and chromatin immunoprecipitation (ChIP) assays.

Isogenic cell line pairs (wild-type vs. ZNF341 knockout) are powerful tools for drug screening. They can be used to identify compounds that restore STAT3 expression or function, potentially providing therapeutic options for IMD56. High-throughput screens can be performed using cell viability or reporter assays. Additionally, these models can be used to study drug resistance mechanisms. For example, if a drug targets the STAT3 pathway, ZNF341 knockout cells may show altered sensitivity, providing insights into resistance mechanisms. Furthermore, gene-edited cells can be used to test the efficacy of gene therapy approaches, such as CRISPR-based correction of ZNF341 mutations.

CRISPR synthetic lethality screens can identify genes that are essential for the survival of ZNF341-deficient cells but not wild-type cells. These genes may serve as potential drug targets. For example, a genome-wide CRISPR screen in ZNF341 knockout cells could reveal dependencies on alternative signaling pathways, such as the MAPK pathway, that could be targeted therapeutically. Additionally, gene-edited cells can be used to identify biomarkers of disease severity or response to treatment. By analyzing the secretome or cell surface markers of ZNF341-deficient cells, researchers can discover novel biomarkers that could be used for diagnosis or monitoring.